A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (ASTRAAS)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
IONIS-AGT-LRx
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Hypertensive, AGT, Angiotensinogen, Blood Pressure
Eligibility Criteria
Inclusion Criteria:
- Males or females aged 18-80 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent
- Females: must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal
- Males must be abstinent, surgically sterile or if engaged in sexual relations with a woman of childbearing potential (WOCBP), a highly effective contraceptive method must be used
- Body mass index (BMI) ≤ 45.0 kilograms per square meter (kg/m^2)
- At screening, the participant must have been on a stable, maximally tolerated regimen (per Investigator judgement) of 3 or more antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study. The combination of antihypertensive medications must be in the following categories: a) angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), b) beta blocker: c) calcium channel blocker d) diuretic, e) alpha-1 blocker f) centrally acting sympatholytic agent or g) direct acting vasodilators (e.g. hydralazine)
Exclusion Criteria:
- Clinically significant abnormalities in screening laboratory results, medical history according to Investigator judgment
- History of secondary hypertension (HTN) including, but not limited to any of the following: renovascular HTN (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced HTN
The use of the following at time of screening and during the course of the study:
- Other medications for the treatment of HTN (e.g., minoxidil, diazoxide, renin inhibitors)
- Medications that may cause hyperkalemia unless on a stable dose at least 1 month prior to the screening visit and no known history of hyperkalemia per Investigator judgement
- Use of oral anticoagulants, unless stable for 4 weeks prior to the first dose of study drug and regular monitoring must be performed per clinical practice during the study unless the participant is receiving vitamin K agonists. If the participant is receiving vitamin K antagonists (e.g., warfarin) international normalized ratio (INR) should be in therapeutic range, as established by the Investigator, for 4 weeks prior to the first dose
- Chronic administration of NSAIDs or COX-2 inhibitors (except aspirin for cardiovascular disease provided the total daily dose does not exceed 325 mg)
- History of bleeding diathesis, coagulopathy, immune thrombocytopenic purpura (ITP), thrombotic cytopenic purpura (TTP), or any qualitative or quantitative platelet defect
Unstable/underlying known cardiovascular disease defined as:
- Any history of congestive heart failure (New York Heart Association [NYHA] Class III-IV)
- Any history of previous myocardial infarction, coronary revascularization, unstable or stable angina pectoris ˂ 1 year prior to screening
- Any hemodynamically unstable atrial or ventricular arrhythmias
- Significant uncorrected valvular heart disease
- Any history of stroke or transient ischemic attack < 1 year prior to screening
- A cardiac valve repair, cardiac device implantation, and/or a hospitalization for heart failure within 3 months of screening
- Participant works nighttime shifts (e.g., 11 PM to 7 AM)
Sites / Locations
- Pinnacle Research Group
- Central Research Associates, Inc.
- Achieve Clinical Research, LLC
- Cahaba Research, Inc.
- Syed Research Consultants LLC
- Cardiology and Medicine Clinic
- Advanced Research Center
- National Research Institute - Huntington Park
- RESPIRE Research
- Clinical Trials Research
- Catalina Research Institute
- San Fernando Valley Health Institute
- Creekside Endocrine Associates, PC
- Chase Medical Research LLC
- ALL Medical Research, LLC
- Nature Coast Clinical Research - Crystal River
- East Coast Institute for Research
- Canvas Clinical Research
- AMPM Research Clinic
- Allied Biomedical Research Institute, Inc.
- Advanced Research Institute Inc
- Ocala Research Institute
- Progressive Medical Research
- Gwinnett Research Institute
- Sandhill Research, LLC
- Georgia Institute for Clinical Research
- Eagle Clinical Research
- Clinical Investigation Specialists, Inc. - Wauconda
- The Research Group of Lexington, LLC
- Louisiana Heart Center
- Clinical Trials of America, LLC - Monroe, LA
- BioPharm Clinical Research
- Palm Research Center, Inc.
- NY Scientific
- Summit Research Group, LLC
- Conrad Clinical Research
- South Oklahoma Heart Research
- Health Concepts Research
- Chattanooga Research & Medicine, PLLC
- Holston Medical Group
- North Texas Research Associates
- Juno Research, LL
- Protenium Clinical Research, LLC
- Laguna Clinical Research Associates
- Kalo Clinical Research
- Manassas Clinical Research Center
- York Clinical Research LLC
- TPMG Clinical Research
- Ecogene-21
- CardioVasc HR
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
IONIS-AGT-LRx
Placebo
Arm Description
Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.
IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.
Outcomes
Primary Outcome Measures
Change in Seated Automated Office Systolic Blood Pressure (SBP) from Baseline to Study Day 85
Secondary Outcome Measures
Change from Baseline in plasma AGT to each scheduled, post-baseline visit
Change from Baseline to Study Day 85 in 24-hour mean SBP measured by ambulatory blood pressure monitoring (ABPM)
Change from Baseline to Study Day 85 in 24-hour mean Diastolic Blood Pressure (DBP) measured by ABPM
Percentage of participants reaching the goals of seated automated office seated SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and both during the study (excluding participants with a baseline SBP of ≤ 140 mmHg)
Percentage of participants reaching the goals of automated office seated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and both during the study
Change from Baseline on seated automated office SBP to each scheduled, post-Baseline visit
Change from Baseline on seated automated office DBP to each scheduled, post-Baseline visit
Full Information
NCT ID
NCT04714320
First Posted
January 14, 2021
Last Updated
February 18, 2023
Sponsor
Ionis Pharmaceuticals, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT04714320
Brief Title
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
Acronym
ASTRAAS
Official Title
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients With Uncontrolled Blood Pressure
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
March 4, 2021 (Actual)
Primary Completion Date
September 15, 2022 (Actual)
Study Completion Date
September 20, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ionis Pharmaceuticals, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx on ambulatory blood pressure, seated automated office SBP, seated automated office diastolic blood pressure (DBP), and plasma angiotensinogen (AGT) at each scheduled visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.
Detailed Description
This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 150 participants. Participants will be randomized in a 2:1 ratio and will receive a once-weekly subcutaneous (SC) treatment with either IONIS-AGT-LRx or matching placebo. The length of participation in the study will be approximately 31 weeks, which includes an up to 6-week screening period, a 12-week treatment period, and a 13-week post-treatment period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Hypertensive, AGT, Angiotensinogen, Blood Pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
160 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IONIS-AGT-LRx
Arm Type
Experimental
Arm Description
Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
IONIS-AGT-LRx
Other Intervention Name(s)
ISIS 757456
Intervention Description
Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
IONIS-AGT-LRx-matching placebo will be administered by SC injection.
Primary Outcome Measure Information:
Title
Change in Seated Automated Office Systolic Blood Pressure (SBP) from Baseline to Study Day 85
Time Frame
Baseline to Day 85
Secondary Outcome Measure Information:
Title
Change from Baseline in plasma AGT to each scheduled, post-baseline visit
Time Frame
Baseline up to Day 169
Title
Change from Baseline to Study Day 85 in 24-hour mean SBP measured by ambulatory blood pressure monitoring (ABPM)
Time Frame
Baseline to Day 85
Title
Change from Baseline to Study Day 85 in 24-hour mean Diastolic Blood Pressure (DBP) measured by ABPM
Time Frame
Baseline up to Day 85
Title
Percentage of participants reaching the goals of seated automated office seated SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and both during the study (excluding participants with a baseline SBP of ≤ 140 mmHg)
Time Frame
Up to Day 169
Title
Percentage of participants reaching the goals of automated office seated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and both during the study
Time Frame
Baseline up to Day 169
Title
Change from Baseline on seated automated office SBP to each scheduled, post-Baseline visit
Time Frame
Baseline up to Day 169
Title
Change from Baseline on seated automated office DBP to each scheduled, post-Baseline visit
Time Frame
Baseline up to Day 169
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females aged 18-80 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent
Females: must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal
Males must be abstinent, surgically sterile or if engaged in sexual relations with a woman of childbearing potential (WOCBP), a highly effective contraceptive method must be used
Body mass index (BMI) ≤ 45.0 kilograms per square meter (kg/m^2)
At screening, the participant must have been on a stable, maximally tolerated regimen (per Investigator judgement) of 3 or more antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study. The combination of antihypertensive medications must be in the following categories: a) angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), b) beta blocker: c) calcium channel blocker d) diuretic, e) alpha-1 blocker f) centrally acting sympatholytic agent or g) direct acting vasodilators (e.g. hydralazine)
Exclusion Criteria:
Clinically significant abnormalities in screening laboratory results, medical history according to Investigator judgment
History of secondary hypertension (HTN) including, but not limited to any of the following: renovascular HTN (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced HTN
The use of the following at time of screening and during the course of the study:
Other medications for the treatment of HTN (e.g., minoxidil, diazoxide, renin inhibitors)
Medications that may cause hyperkalemia unless on a stable dose at least 1 month prior to the screening visit and no known history of hyperkalemia per Investigator judgement
Use of oral anticoagulants, unless stable for 4 weeks prior to the first dose of study drug and regular monitoring must be performed per clinical practice during the study unless the participant is receiving vitamin K agonists. If the participant is receiving vitamin K antagonists (e.g., warfarin) international normalized ratio (INR) should be in therapeutic range, as established by the Investigator, for 4 weeks prior to the first dose
Chronic administration of NSAIDs or COX-2 inhibitors (except aspirin for cardiovascular disease provided the total daily dose does not exceed 325 mg)
History of bleeding diathesis, coagulopathy, immune thrombocytopenic purpura (ITP), thrombotic cytopenic purpura (TTP), or any qualitative or quantitative platelet defect
Unstable/underlying known cardiovascular disease defined as:
Any history of congestive heart failure (New York Heart Association [NYHA] Class III-IV)
Any history of previous myocardial infarction, coronary revascularization, unstable or stable angina pectoris ˂ 1 year prior to screening
Any hemodynamically unstable atrial or ventricular arrhythmias
Significant uncorrected valvular heart disease
Any history of stroke or transient ischemic attack < 1 year prior to screening
A cardiac valve repair, cardiac device implantation, and/or a hospitalization for heart failure within 3 months of screening
Participant works nighttime shifts (e.g., 11 PM to 7 AM)
Facility Information:
Facility Name
Pinnacle Research Group
City
Anniston
State/Province
Alabama
ZIP/Postal Code
36207
Country
United States
Facility Name
Central Research Associates, Inc.
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Facility Name
Achieve Clinical Research, LLC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
Facility Name
Cahaba Research, Inc.
City
Pelham
State/Province
Alabama
ZIP/Postal Code
35124
Country
United States
Facility Name
Syed Research Consultants LLC
City
Sheffield
State/Province
Alabama
ZIP/Postal Code
35660
Country
United States
Facility Name
Cardiology and Medicine Clinic
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72204
Country
United States
Facility Name
Advanced Research Center
City
Anaheim
State/Province
California
ZIP/Postal Code
92805
Country
United States
Facility Name
National Research Institute - Huntington Park
City
Huntington Park
State/Province
California
ZIP/Postal Code
90255
Country
United States
Facility Name
RESPIRE Research
City
La Mesa
State/Province
California
ZIP/Postal Code
91942
Country
United States
Facility Name
Clinical Trials Research
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Catalina Research Institute
City
Montclair
State/Province
California
ZIP/Postal Code
91763
Country
United States
Facility Name
San Fernando Valley Health Institute
City
Van Nuys
State/Province
California
ZIP/Postal Code
91405
Country
United States
Facility Name
Creekside Endocrine Associates, PC
City
Denver
State/Province
Colorado
ZIP/Postal Code
80246
Country
United States
Facility Name
Chase Medical Research LLC
City
Waterbury
State/Province
Connecticut
ZIP/Postal Code
06708
Country
United States
Facility Name
ALL Medical Research, LLC
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Nature Coast Clinical Research - Crystal River
City
Crystal River
State/Province
Florida
ZIP/Postal Code
34429
Country
United States
Facility Name
East Coast Institute for Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Canvas Clinical Research
City
Lake Worth
State/Province
Florida
ZIP/Postal Code
33467
Country
United States
Facility Name
AMPM Research Clinic
City
Miami Gardens
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Allied Biomedical Research Institute, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
Advanced Research Institute Inc
City
New Port Richey
State/Province
Florida
ZIP/Postal Code
34653
Country
United States
Facility Name
Ocala Research Institute
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
Progressive Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32124
Country
United States
Facility Name
Gwinnett Research Institute
City
Buford
State/Province
Georgia
ZIP/Postal Code
30519
Country
United States
Facility Name
Sandhill Research, LLC
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Facility Name
Georgia Institute for Clinical Research
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Eagle Clinical Research
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60621
Country
United States
Facility Name
Clinical Investigation Specialists, Inc. - Wauconda
City
Wauconda
State/Province
Illinois
ZIP/Postal Code
60084
Country
United States
Facility Name
The Research Group of Lexington, LLC
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
Louisiana Heart Center
City
Slidell
State/Province
Louisiana
ZIP/Postal Code
70458
Country
United States
Facility Name
Clinical Trials of America, LLC - Monroe, LA
City
West Monroe
State/Province
Louisiana
ZIP/Postal Code
71291
Country
United States
Facility Name
BioPharm Clinical Research
City
Caro
State/Province
Michigan
ZIP/Postal Code
48723
Country
United States
Facility Name
Palm Research Center, Inc.
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89148
Country
United States
Facility Name
NY Scientific
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
Summit Research Group, LLC
City
Stow
State/Province
Ohio
ZIP/Postal Code
44224
Country
United States
Facility Name
Conrad Clinical Research
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73013
Country
United States
Facility Name
South Oklahoma Heart Research
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73135
Country
United States
Facility Name
Health Concepts Research
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57702
Country
United States
Facility Name
Chattanooga Research & Medicine, PLLC
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
Holston Medical Group
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
Facility Name
North Texas Research Associates
City
Allen
State/Province
Texas
ZIP/Postal Code
75013
Country
United States
Facility Name
Juno Research, LL
City
Houston
State/Province
Texas
ZIP/Postal Code
77040
Country
United States
Facility Name
Protenium Clinical Research, LLC
City
Hurst
State/Province
Texas
ZIP/Postal Code
76054
Country
United States
Facility Name
Laguna Clinical Research Associates
City
Laredo
State/Province
Texas
ZIP/Postal Code
78041
Country
United States
Facility Name
Kalo Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84102
Country
United States
Facility Name
Manassas Clinical Research Center
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20110
Country
United States
Facility Name
York Clinical Research LLC
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23510
Country
United States
Facility Name
TPMG Clinical Research
City
Williamsburg
State/Province
Virginia
ZIP/Postal Code
23188
Country
United States
Facility Name
Ecogene-21
City
Chicoutimi
State/Province
Quebec
ZIP/Postal Code
G7H 7K9
Country
Canada
Facility Name
CardioVasc HR
City
Saint-Jean-sur-Richelieu
State/Province
Quebec
ZIP/Postal Code
J3A 1J2
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
We'll reach out to this number within 24 hrs